NEW HAVEN, Conn., Sept. 21, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that it will host a live webcast of its inaugural Analyst Day on Thursday, September 27, 2012 beginning at 1:00 p.m. Eastern Time.
The senior management team, led by Michael Kishbauch, President and Chief Executive Officer of Achillion, will review Achillion's hepatitis C (HCV) programs and future clinical development plans. In addition, presentations are expected to be made by Alan Perelson, Ph.D., Senior Fellow, Los Alamos National Laboratory; Douglas Dieterich, M.D., Professor of Medicine, Liver Diseases, Mount Sinai School of Medicine; and Fred Poordad, M.D., Chief Medical Officer of the Texas Liver Institute / Alamo Medical Research; with Q&A sessions facilitated by Kurt Graves, Director of Achillion, and Chairman, President and Chief Executive Officer of Intarcia Therapeutics.
The webcast will be accessible from the Investor Relations page on the Company's website at http://www.achillion.com . A replay of the webcast will be archived on the Company's website beginning approximately two hours following the live event.About Achillion Pharmaceuticals Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including HCV and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.
CONTACT: Company Contact: Glenn Schulman Achillion Pharmaceuticals, Inc. Tel. (203) 624-7000 email@example.com Media: Christin Culotta Miller Ogilvy PR Tel. (646) 229-5178 firstname.lastname@example.org Investors: Mary Kay Fenton Achillion Pharmaceuticals, Inc. Tel. (203) 624-7000 email@example.com Investors: Seth Lewis The Trout Group, LLC Tel. (646) 378-2952 firstname.lastname@example.org
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV